StreetInsider.com News Articles

Exelixis (EXEL) PT Raised to $49 at Barclays

Tue, 14 Jul 2026 05:12:14 -0400

Barclays analyst Etzer Darout raised the price target on Exelixis (NASDAQ: EXEL) to $49.00 (from $45.00) while maintaining a Equalweight rating.

Exelixis (EXEL) PT Raised to $49 at Wells Fargo

Mon, 13 Jul 2026 06:28:28 -0400

Wells Fargo analyst Eva Fortea Verdejo raised the price target on Exelixis (NASDAQ: EXEL) to $49.00 (from $40.00) while maintaining a Equal Weight rating.

Exelixis (EXEL) PT Raised to $49 at Wells Fargo

Mon, 13 Jul 2026 06:28:21 -0400

Wells Fargo analyst Eva Fortea Verdejo raised the price target on Exelixis (NASDAQ: EXEL) to $49.00 (from $40.00) while maintaining a Equal Weight rating.

Exelixis (EXEL) PT Raised to $46 at RBC Capital

Tue, 07 Jul 2026 08:00:02 -0400

RBC Capital analyst Leonid Timashev raised the price target on Exelixis (NASDAQ: EXEL) to $46.00 (from $43.00) while maintaining a Sector Perform rating.

Exelixis (EXEL) PT Raised to $56 at Truist Securities

Tue, 07 Jul 2026 07:09:04 -0400

Truist Securities analyst Gregory Renza raised the price target on Exelixis (NASDAQ: EXEL) to $56.00 (from $54.00) while maintaining a Hold rating.

Exelixis (EXEL) PT Raised to $52 at UBS on Upcoming Catalysts

Thu, 02 Jul 2026 08:45:02 -0400

UBS analyst Ashwani Verma raised the price target on Exelixis (NASDAQ: EXEL) to $52.00 (from $43.00) while maintaining a Neutral rating.

The analyst commented, "We see balanced risk-reward for EXEL as we approach key upcoming catalysts (nccRCC readout/CRC launch). We note that EXEL stock has performed well recently despite unfavorable updates from competitors and STELLAR-303. We believe zanza is well positioned for success in the upcoming nccRCC readout, which could drive additional stock upside. If the nccRCC readout is positive, we note there is still debate on whether zanza can out-perform Cabo in RCC. We think zanza expansion into additional indications will be key

Exelixis (EXEL) PT Raised to $52 at UBS on Upcoming Catalysts

Thu, 02 Jul 2026 08:45:02 -0400

UBS analyst Ashwani Verma raised the price target on Exelixis (NASDAQ: EXEL) to $52.00 (from $43.00) while maintaining a Neutral rating.

H.C. Wainwright Reiterates Buy Rating on Exelixis (EXEL)

Thu, 02 Jul 2026 06:42:31 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $56.00 price target on Exelixis (NASDAQ: EXEL).

The analyst commented: "Last week, Exelixis announced results from the final analysis of the dual primary endpoint of OS in the subset of patients without active liver metastases (non-liver metastases, NLM) in the phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq) versus regorafenib in previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). Per the press release, the results showed a non-statistically significant trend in OS favoring the combination in the NLM subpopulation (stratified hazard ratio: 0.83; 95% confidence interval:

Truist Securities Assumes Exelixis (EXEL) at Hold

Thu, 25 Jun 2026 06:17:47 -0400

(Updated - June 25, 2026 6:17 AM EDT)

Truist Securities analyst Gregory Renza assumes coverage on Exelixis (NASDAQ: EXEL) with a Hold rating and a price target of $54.00 (from $51.00).

The analyst commented: "We assume coverage of EXEL with a Hold rating (from Buy) and a $54 PT (from $51). Cabometyx (Cabo') serves as a key topline driver for EXEL, as a leading TKI in RCC, and a launch underway in NETs, with a 2031 LOE approaching. Next-gen zanzalintinib (zanza') brings a Dec. 3 PDUFA ahead for 3L+ mCRC (+ atezolizumab), which could add another revenue leg to EXEL's story, though

Truist Securities Assumes Exelixis (EXEL) at Hold

Thu, 25 Jun 2026 06:17:47 -0400

(Updated - June 25, 2026 6:17 AM EDT)

Truist Securities analyst Gregory Renza assumes coverage on Exelixis (NASDAQ: EXEL) with a Hold rating and a price target of $54.00 (from $51.00).

Truist Securities Assumes Exelixis (EXEL) at Hold

Thu, 25 Jun 2026 06:17:47 -0400

(Updated - June 25, 2026 6:17 AM EDT)

Truist Securities analyst Gregory Renza assumes coverage on Exelixis (NASDAQ: EXEL) with a Hold rating and a price target of $54.00 (from $51.00).

Exelixis (EXEL) Reiterated at Market Outperform by Citizens on Q2 Cabo Script Growth

Wed, 24 Jun 2026 04:09:23 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $55.00 price target on Exelixis (NASDAQ: EXEL).

The analyst commented, "The non-liver metastasis (NLM) subgroup in the positive Ph3 STELLAR-303 study comparing zanzalintinib and atezolizumab to regorafenib showed a positive trend in OS benefit, but was not statistically significant. Exelixis expects the zanzalintinib combo to be approved in all 3L+ CRC patients (incl. NLM patients), consolidating a fragmented market. Separately, with two weeks of data missing in 2Q, we point to high cabo script growth in 2Q, which leads us to increase our price target to $55 (DCF-derived) from $50 previously.

Morgan Stanley on Exelixis (EXEL): today's update 'mixed-to-negative at the margin'

Mon, 22 Jun 2026 12:29:24 -0400

Morgan Stanley analyst Sean Laaman reiterated an Equalweight rating and $50.00 price target on Exelixis (NASDAQ: EXEL)

The analyst commented, "Today’s Exelixis update is clinically mixed-to-negative at the margin: Exelixis Press Release Update on STELLAR-303 Trial in Metastatic CRC reports that STELLAR-303 did not hit statistical significance on the second dual primary endpoint, OS in patients without active liver metastases/NLM, with HR 0.83, 95% CI 0.66–1.05, p=0.1185, and median OS 15.9 months vs. 12.7 months for zanzalintinib + atezolizumab vs. regorafenib; safety was consistent with the prior ITT readout and no new safety signals were identified. Noted that a trend in

Exelixis colorectal cancer trial misses one of two survival goals